Extended Data Fig. 8Figure 11
CONSORT diagram for case selection for first-line CDK4/6i + ET outcomes stratified by allele-specific copy number of RB1. ASCN analysis was performed on tumor samples collected prior to initiation of first-line CDK4/6i + ET. Samples were excluded (n = 158) for technical reasons including low purity or paucity of heterozygous SNPs in the region of interest. The CONSORT diagram describes the clinical outcomes analysis on the 547 samples remaining, as well as the matched pairs analysis on the 405 samples with corresponding post progression biopsies.